Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT1041220111
jRCT1041220111CompletedNot Applicable

FDG-PET study of re-injury prevention training after ACL reconstruction

Toshifumi Gabata0 sites10 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10
Primary Endpoint
-
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Prevention Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
18age old over to No limit (—)
Sex
Male

Inclusion Criteria

  • •Patients who have undergone reconstructive surgery for anterior cruciate ligament injuries
  • •Adult male patients who understand the study and are able to exercise using the FIFA11+.
  • •Patients who have given their free and voluntary written consent to participate in this study after obtaining sufficient informed consent.

Exclusion Criteria

  • •Those who have suffered an anterior cruciate ligament injury due to a cause other than sports trauma.
  • •Persons who have been diagnosed with diabetes mellitus and are under treatment, or who have an HbA1c of 6.5% or higher without treatment.
  • •Patients with a history of medical disease (e.g. heart failure) who should avoid exercise load
  • •Patients with complaints in the lower limbs except knee joint pain
  • •Subjects with a history of allergy to the drug (18F-FDG) after undergoing a PET scan in the past
  • •Subjects who are judged to be inappropriate as research subjects by the principal investigator or subinvestigator

Outcomes

Primary Outcomes

-

Skeletal muscle accumulation in PET images

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Toshifumi Gabata

Similar Trials

Active, not recruiting
Phase 1
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD
CTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59
Recruiting
Not Applicable
ACE study (ACE study)
jRCT103224050764
Recruiting
Not Applicable
LOME-PECT trial (LOME-PECT trial)
jRCTs031230684200
Recruiting
Not Applicable
PCCT study
jRCTs032220618360
Not yet recruiting
Not Applicable
AAC (aac)
jRCT1070240018Kumamoto Health Science University Reseach Grant Number 2024-C-0120